Adalvo Partners With AmbioPharm For Several Complex Products

Development And Licensing Partnership Includes ‘Difficult-To-Make’ Peptide Products

 
• By Akriti Seth

Alvogen’s newly created B2B unit, Adalvo, has partnered with AmbioPharm for the co-development and licensing for the commercialization of several complex pharmaceutical products, including difficult-to-make peptides, in key global markets.

Strategic_Partnership
Adalvo and AmbioPharm have partnered on a basket of difficult-to-make peptides with a potential market of $3bn • Source: Shutterstock

More from Deals

More from Business